Siegfried grows as world-class pharmaceutical contract manufacturer
Outsourcing has become increasingly prevalent in the pharmaceutical industry amid soaring research and development costs, mounting pricing pressures and more stringent regulatory requirements. Well-positioned to capitalise on this growing trend is Siegfried Holding, a Swiss contract manufacturing organisation (CMO) with more than 140 years of experience and competency in pharmaceuticals and chemistry.
Outsourcing has become increasingly prevalent in the pharmaceutical industry amid soaring research and development costs, mounting pricing pressures and more stringent regulatory requirements. Well-positioned to capitalise on this growing trend is Siegfried Holding, a Swiss contract manufacturing organisation (CMO) with more than 140 years of experience and competency in pharmaceuticals and chemistry.
"As a CMO, we act as a reinsurer to pharmaceutical companies, helping them avoid the risks of investing in costly production sites during the uncertain stages of drug development," says Dr Rudolf Hanko, Siegfried's CEO. "We help clients focus on their core competencies, achieve cost savings and reduce burn rates."
Once a dedicated pharmaceutical company, Siegfried has transformed into a fully integrated supplier and service provider to major and start-up pharmaceutical players. In addition to offering operational stability, Swiss quality and intellectual property assurance, the company is renowned for its innovative value proposition. Siegfried is among the few with the capability to develop and produce active pharmaceutical ingredients (APIs) and finished dosage forms under one roof. Its comprehensive service portfolio encompasses custom development, registration, manufacturing, packaging and logistics.
Through acquisitions and organic growth, Siegfried has achieved greater geographical diversification. It has its headquarters and main production facility in Zofingen, Switzerland, and maintains drug manufacturing sites in the United States, Malta and Nantong, China - all fully compliant with internationally recognised standards of current good manufacturing practice. The Nantong facility, located northwest of Shanghai, was brought online last year and is equipped to produce APIs and intermediates.
"Key to the success of our Nantong set-up is our co-operation with Chinese development organisation Nantong Economic and Technological Development Area (NETDA)," Hanko says. "With NETDA's support, we were able to address the complexities of establishing manufacturing operations on the mainland."
Simultaneous with the Nantong project is the construction of an API production building in Zofingen to replace older, less-efficient facilities. The comparable technical designs of the Zofingen and Nantong sites will streamline product transfer between the two locations and simplify technical and regulatory issues.
"The Nantong and Zofingen facilities play a vital role in our planned shift from being a vertically integrated organisation to a horizontally integrated operation," Hanko says. "We see the change to provide Siegfried the greatest operating leverage and opportunity for success. This is us getting ahead of the wave, preparing for a major marketplace transformation."
http://www.siegfried.ch
